Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized placebo-controlled study of PF-07275315 in adults with moderate to severe chronic obstructive pulmonary disease
CTR20261205Phase 3Active
- Sponsor
- Pfizer
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tilrekimig in chronic obstructive pulmonary disease (COPD), sponsored by Pfizer. Started May 2026; status: active.
02
Drugs
tilrekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20261205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261205.